News

3rd African International Conference on Immunity (AICI)

The third AICI was held on November 3–6, 2018 at the Elephant Hills Hotel in Victoria Falls, Zimbabwe, and hosted more than 200 attendees. The main theme of the conference was “Immunity in Infectious Diseases and Allergy.” The meeting focused on conditions of impaired immunity (i.e., AIDS, tuberculosis, malaria, and opportunistic infections) and excess immunity (i.e., autoimmunity and allergy) with reference to how these conditions interact with each other at molecular, cellular, and clinical levels.

Read more...

Conference "Actual problems of clinical immunology"

Prof. Rudolf Valenta was invited to serve as a keynote speaker at the Interregional Scientific and Practical Conference “Actual problems of clinical immunology” held on March 1, 2019 in Voronezh, Russia. This should foster a co-operation between the Medical University of Vienna and the Voronezh State Medical University named after N.N. Burdenko (VSMU).

We share the pdf English translation of a Russian press report. For the original article, pls. follow the link: https://vrn.vestipk.ru/archives/143888

The 'Cat Project': Will scientists soon have a vaccine for feline allergies?

Russian and Austrian scientists are developing a genetically engineered vaccine.
Sechenov University in Moscow and the Medical University of Vienna launched the 'Cat Project', which hopes to find new medication that will be effective against all known feline allergens:
https://www.rbth.com/science-and-tech/328625-cat-project-allergy-vaccine-cure (© Russia Beyond, June 27, 2018)

News from the 10th Hong Kong Allergy Convention - HKAC 2018

Prof. Rudolf Valenta had the honour to serve as a keynote speaker at the 10th Hong Kong Allergy Convention HKAC 2018 meeting.
He attended in this context a press conference dedicated to the allergen-specific immunotherapy which has been reported in TVB news, the most popular news channel in Hong Kong.
We are glad to share the video clip, highlighting new helpful approaches made in the allergy research in Austria, commented by Prof. Rudolf Valenta, speaker of the SFB F46 Allergy Reseacht Program.
For more details pls. follow the link for the video clip: https://1drv.ms/v/s!AnkElLk76FSfgdps39bPdSplPfEVVQ (© TVB news, Oct. 5, 2018)

1st Moscow Molecular Allergology Meeting (MMAM)

The 1st Moscow Molecular Allergology Meeting (MAMM) took place in November 27, 2018 in Moscow at AZIMUT Hotel Olympic: www.nrcii.ru/sobytiya/mmam/ 
The meeting was very well visited and strengthened successfully the collaborations in the field of allergy research.

Photo gallery

 

Our genes dictate who develops an allergy

Vaccinations to protect against allergies are the vision – Immunology Week from 22 – 28 April 2018

(Vienna, 19 April 2018) Whether or not you develop an allergy is largely dependent upon genetic factors. This is the main finding of a study recently published in EBioMedicine, just in time for World Allergy Week (22-28. April 2018, www.worldallergyweek.org). The study was supervision of Winfried F. Pickl from MedUni Vienna's Institute of Immunology. The Vienna researchers were able to show that the gene HLA-DR1 and allergen-specific, reactive T-cells play a major role in the development of an allergy to mugwort, for example – assuming, of course, that one is exposed to the source of the allergen.

Read more...

Recombinant grass pollen allergy vaccine ameliorates symptoms of grass pollen-induced hayfever in a double-blind, placebo-controlled multicenter field phase IIb trial

First vaccine in the world developed against grass pollen allergy

(Vienna, 18 January 2018) Viennese product: collaboration between MedUni Vienna and Biomay AG
Around 400 million people world-wide suffer in some form or other from a grass pollen allergy (rhinitis) – with the usual symptoms such as a runny nose, cough and severe breathing problems. In collaboration with the Viennese firm Biomay AG, MedUni Vienna researchers at the Institute of Pathophysiology and Allergy Research have now shown in a Phase II-b study with 180 patients in 11 European centres, that four injections of the synthetically manufactured vaccine BM32 in the first year and a top-up in the second year of treatment relieve the sufferers' symptoms by at least 25%.”

Read more...

Rudolf Valenta awarded Russian "Mega Grant"

Research funding from Russian government for joint project on birch pollen allergy

(Moscow/Vienna, 14 December2017) Rudolf Valenta, MedUni Vienna allergy researcher, has been awarded a so-called "Mega Grant" by the Russian government for a research project to be conducted in collaboration with Musa Khaitov from the NRC Institute of Immunology FBMA in Moscow to study the immune response to the birch pollen allergen "Bet v 1".
The grant is worth 90 million roubles (around €1.2 million).

Read more...

New approach to predict respiratory allergy in early childhood

(Solna/Vienna, 12-12-2017) Immune response in early childhood to a handful of allergen moleculescan predict the onset of allergic rhinitis and asthma in adolescence, suggests a new study in EBioMedicine by researchers at KarolinskaInstitutet in Sweden and the Medical University of Vienna, Austria. The findings could accelerate the development of preventive strategies and novel treatments for respiratory allergy in children.

Read more...

MedUni Vienna becomes WAO Center of Excellence

Allergy research recognised by the World Allergy Organization

center-of-excellenceMedUni Vienna has been chosen by the Excellence Selection Committee of the World Allergy Organization (WAO) to be one of its WAO Centers of Excellence.

MedUni Vienna is now one of only 30 WAO Centers of Excellence (provisionally until 2020).
The purpose of the WAO Centers of Excellence is to intensify and accelerate multidisciplinary scientific and clinical innovation, education and advocacy worldwide in the field of allergy, asthma and clinical immunology.

Read more...